Conversely, Nrf2 activation—by pharmacological agents or genetic means—upregulates GSH, GPX4, and FTH1, mitigating podocyte injury and DN progression (120, 148, 149). This evidence concerns the gene NFE2L2 and liver dysplastic nodule.